Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Combining rare and common genetic variants improves population risk stratification for breast cancer

View ORCID ProfileAlexandre Bolze, Daniel Kiser, View ORCID ProfileKelly M. Schiabor Barrett, Gai Elhanan, Jamie M. Schnell Blitstein, Iva Neveux, Shaun Dabe, Harry Reed, Alexa Anderson, William J. Metcalf, Ekaterina Orlova, Ildiko Thibodeau, Natalie Telis, Ruomu Jiang, View ORCID ProfileNicole L. Washington, Matthew J. Ferber, Catherine Hajek, View ORCID ProfileElizabeth T. Cirulli, View ORCID ProfileJoseph J. Grzymski
doi: https://doi.org/10.1101/2023.05.17.23290132
Alexandre Bolze
1Helix, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexandre Bolze
  • For correspondence: alexandre.bolze{at}helix.com Joe.Grzymski{at}dri.edu
Daniel Kiser
3Center for Genomic Medicine, Desert Research Institute, Reno, NV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly M. Schiabor Barrett
1Helix, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kelly M. Schiabor Barrett
Gai Elhanan
2Renown Health, Reno, NV, USA
3Center for Genomic Medicine, Desert Research Institute, Reno, NV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie M. Schnell Blitstein
2Renown Health, Reno, NV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iva Neveux
3Center for Genomic Medicine, Desert Research Institute, Reno, NV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaun Dabe
2Renown Health, Reno, NV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry Reed
3Center for Genomic Medicine, Desert Research Institute, Reno, NV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexa Anderson
2Renown Health, Reno, NV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Metcalf
2Renown Health, Reno, NV, USA
3Center for Genomic Medicine, Desert Research Institute, Reno, NV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ekaterina Orlova
4Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ildiko Thibodeau
1Helix, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie Telis
1Helix, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruomu Jiang
1Helix, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole L. Washington
1Helix, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicole L. Washington
Matthew J. Ferber
1Helix, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Hajek
1Helix, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth T. Cirulli
1Helix, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth T. Cirulli
Joseph J. Grzymski
2Renown Health, Reno, NV, USA
3Center for Genomic Medicine, Desert Research Institute, Reno, NV, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joseph J. Grzymski
  • For correspondence: alexandre.bolze{at}helix.com Joe.Grzymski{at}dri.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose In the United States, breast cancer clinical risk assessments are inconsistent and inequitable. The previous success of BRCA1 and BRCA2 screening has demonstrated that genetics could be used to reduce these inequities, if they are available and accessible across the population. The aim of this study is to evaluate the performance of different genetic screening approaches to identify women at high-risk of breast cancer in the general population.

Methods We did a retrospective study on 25,591 women participating in the Healthy Nevada Project. Electronic Health Records (EHR) data were used to identify women with a family history of, and women who were diagnosed with breast cancer. The genetic analysis assessed the role of rare predicted loss-of-function (pLOF) variants in BRCA1, BRCA2, PALB2, ATM and CHEK2, as well as the combined role of common variants via a polygenic risk score. Women were considered at high-risk of breast cancer if they had greater than 20% probability of being diagnosed with breast cancer by age 70.

Results Family history of breast cancer (FHx-BrCa) was ascertained on or after the record of breast cancer for 78% of women with both, indicating that this method for risk assessment is not being properly utilized for early screening. Genetics offered an alternative method for risk assessment. 11.4% of women in HNP were at high-risk of breast cancer based on their genetic risk: having a pLOF variant in BRCA1, BRCA2 or PALB2 (hazard ratio = 10.4, 95% confidence interval: 8.1-13.5), or a pLOF variant in ATM or CHEK2 (HR = 3.4, CI: 2.4-4.8), or being in the top 10% of the polygenic risk score distribution (HR = 2.4, CI: 2.0-2.8). We also showed that combining PRS with pLOF in ATM and CHEK2 allowed a better identification of participants with high risk while minimizing false positives. Women with a pLOF in ATM or CHEK2 and in the top 50% of the PRS are at high risk (39.2% probability of breast cancer at age 70), while those with a pLOF in ATM or CHEK2 and in the bottom 50% of the PRS are not at high risk (14.4% probability of breast cancer at age 70).

Conclusion These results suggest that a combined monogenic and polygenic approach may best capture the inherited risk for breast cancer across the population.

Competing Interest Statement

A.B., K.M.S.B., I.T., N.T., R.J., N.L.W., M.J.F., C.H. and E.T.C. are employees of Helix. A patent application has been filed by Helix for the 'Dynamic risk management for breast cancer based on multi-factor genetic testing' with A.B. and J.J.G. as inventors, and its current status is unpublished (application number 63/467,250).

Funding Statement

Funding was provided to the Renown Institute for Health Innovation by Renown Health and the Renown Health Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Healthy Nevada Project study was reviewed and approved by the University of Nevada, Reno Institutional Review Board (project 956068-12). All participants gave their informed consent before participation. All data used for research were de-identified.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

The Healthy Nevada Project data are available to qualified researchers upon request and with permission of the Institute for Health Innovation (IHI) and Helix. Researchers who would like to obtain the raw genotype data related to this study will be presented with a data user agreement, which requires that no participants will be reidentified and no data will be shared between individuals or uploaded onto public domains. The IHI encourages and collaborates with scientific researchers on an individual basis. Examples of restrictions that will be considered in requests to data access include but are not limited to (1) whether the request comes from an academic institution in good standing and will collaborate with our team to protect the privacy of the participants and the security of the data requested, (2) type and amount of data requested, (3) feasibility of the research suggested, and (4) amount of resource allocation for the IHI and Renown Hospital required to support the collaboration. Any correspondence and data availability requests related to Healthy Nevada Project should be addressed to J.J.G. (Joe.Grzymski{at}dri.edu) or Craig Kugler (Craig.Kugler{at}dri.edu).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted May 19, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Combining rare and common genetic variants improves population risk stratification for breast cancer
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Combining rare and common genetic variants improves population risk stratification for breast cancer
Alexandre Bolze, Daniel Kiser, Kelly M. Schiabor Barrett, Gai Elhanan, Jamie M. Schnell Blitstein, Iva Neveux, Shaun Dabe, Harry Reed, Alexa Anderson, William J. Metcalf, Ekaterina Orlova, Ildiko Thibodeau, Natalie Telis, Ruomu Jiang, Nicole L. Washington, Matthew J. Ferber, Catherine Hajek, Elizabeth T. Cirulli, Joseph J. Grzymski
medRxiv 2023.05.17.23290132; doi: https://doi.org/10.1101/2023.05.17.23290132
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Combining rare and common genetic variants improves population risk stratification for breast cancer
Alexandre Bolze, Daniel Kiser, Kelly M. Schiabor Barrett, Gai Elhanan, Jamie M. Schnell Blitstein, Iva Neveux, Shaun Dabe, Harry Reed, Alexa Anderson, William J. Metcalf, Ekaterina Orlova, Ildiko Thibodeau, Natalie Telis, Ruomu Jiang, Nicole L. Washington, Matthew J. Ferber, Catherine Hajek, Elizabeth T. Cirulli, Joseph J. Grzymski
medRxiv 2023.05.17.23290132; doi: https://doi.org/10.1101/2023.05.17.23290132

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)